MANAGEMENT CONSIDERATIONS FOR ORAL TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Shenoy, Samantha [1 ]
Leahey, Sheryl [2 ]
Catamero, Donna [3 ]
O'Rourke, Lisa [4 ]
Gray, Kathleen [5 ]
Rogers, Stephanie [6 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] Mt Sinai Hlth Syst, New York, NY USA
[4] Janssen Res & Dev, Spring House, PA USA
[5] Janssen Res & Dev, Bridgewater, NJ USA
[6] Univ Arkansas Med Sci, Little Rock, AR USA
来源：
ONCOLOGY NURSING FORUM | 2024年 / 51卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Y I38
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Management considerations for dermatologic toxicities associated with talquetamab, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma
    Purcell, Kiah
    Catamero, Donna
    Dai, Victoria
    Feuer, Julia
    Giacoia, Leora
    Leon, Yan
    Lurie, Alaina
    Mitchell, Emily
    Ray, Chloe
    Urena, Annel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S312 - S313
  • [2] MANAGEMENT CONSIDERATIONS FOR DERMATOLOGIC TOXICITIES ASSOCIATED WITH TALQUETAMAB, A GPRC5DxCD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Esler, Elaine
    Ray, Chloe
    Hefner, Kayla
    O'Rourke, Lisa
    Gray, Kathleen
    Gray, Kathleen
    McCluggage, Julie
    ONCOLOGY NURSING FORUM, 2024, 51 (02)
  • [3] Practical management of patients with relapsed/refractory multiple myeloma receiving talquetamab, a GPRC5DxCD3 bispecific antibody: experience in monumenTAL-1
    Catamero, Donna
    Purcell, Kiah
    Ray, Chloe
    Giacoia, Leora
    Leahey, Sheryl
    Born, Patricia
    Kruyswijk, Sandy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S314 - S315
  • [4] Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma
    Verkleij, Christie P. M.
    Broekmans, Marloes E. C.
    van Duin, Mark
    Frerichs, Kristine A.
    Kuiper, Rowan
    de Jonge, A. Vera
    Kaiser, Martin
    Morgan, Gareth
    Axel, Amy
    Boominathan, Rengasamy
    Sendecki, Jocelyn
    Wong, Amy
    Verona, Raluca, I
    Sonneveld, Pieter
    Zweegman, Sonja
    Adams, Homer C., III
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    BLOOD ADVANCES, 2021, 5 (08) : 2196 - 2215
  • [5] Prophylactic Interventions for Oral Toxicities With the GPRC5DxCD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma: An Open-Label, Phase 2, Randomized Study (TALISMAN)
    Popat, Rakesh
    Laheij, Alexa
    van de Donk, Niels
    Doty, Richard
    Omel, Jim
    Lipe, Brea
    Rasche, Leo
    Chari, Ajai
    Kato, Kelly
    Tian, Ken
    Vishwamitra, Deeksha
    Speier, Jacqueline
    Durand, Mathilde
    Northup, Margaret
    Saber, Ibrahim
    Prada, William
    Gray, Kathleen
    Aguilar, Gloria
    Sanchez, Larysa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S79 - S80
  • [6] Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study
    Shkury, Eden
    Hellou, Tamer
    Nevo, Lee
    Avigdor, Abraham
    Magen, Hila
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S88 - S89
  • [7] Pivotal phase 2 MonumenTAL-1 results of talquetamab (tal), a GPRC5DxCD3 bispecific antibody (BsAb), for relapsed/refractory multiple myeloma (RRMM).
    Schinke, Carolina D.
    Touzeau, Cyrille
    Minnema, Monique C.
    van de Donk, Niels W. C. J.
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Rasche, Leo
    Ye, Jing Christine
    Vishwamitra, Deeksha
    Ma, Xuewen
    Qin, Xiang
    Campagna, Michela
    Masterson, Tara J.
    Hilder, Brandi
    Tolbert, Jaszianne A.
    Renaud, Thomas
    Goldberg, Jenna
    Heuck, Christoph
    Chari, Ajai
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Pivotal Phase 2 MonumenTAL-1 results of Talquetamab (tal), a GPRC5DxCD3 Bispecific Antibody (BsAb), for Relapsed/Refractory Multiple Myeloma (RRMM)
    Schinke, C.
    Touzeau, C.
    Minnema, M. C.
    van de Donk, N. W.
    Rodriguez-Otero, P.
    Mateos, M. -V.
    Rasche, L.
    Ye, J. C.
    Vishwamitra, D.
    Ma, X.
    Qin, X.
    Campagna, M.
    Masterson, T.
    Hilder, B.
    Tolbert, J.
    Renaud, T.
    Goldberg, J.
    Heuck, C.
    Chari, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 82 - 83
  • [9] Efficacy and Safety of Talquetamab, a GPRC5DxCD3 Bispecific Antibody, in Japanese Patients with Relapsed/Refractory Multiple Myeloma from the Phase 1/2 Monumental-1 Study
    Ito, Shigeki
    Kuroda, Yoshiaki
    Sunami, Kazutaka
    Matsue, Kosei
    Imada, Kazunori
    Tamura, Hideto
    Takamoto, Mikihiro
    Yamazaki, Hiroshi
    Fujikawa, Ei
    Pei, Lixia
    Masterson, Tara J.
    Campagna, Michela
    Lau, Bonnie W.
    Takamatsu, Yasushi
    BLOOD, 2024, 144 : 7011 - 7012
  • [10] Talquetamab, a Novel Anti-Myeloma GPRC5DxCD3 Bispecific Antibody, is Associated with Increased Oropharyngeal FDG Uptake
    Trak, J.
    Mouhieddine, T.
    Lancman, G.
    Sanchez, L.
    Chari, A.
    Ghesani, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S571 - S571
12345